Abstract
The objective of this study was to examine the action of isoflavone on human endometrial cells. We determined the effect of a daidzein-rich isoflavone aglycone mixture (Dr. AglyMax®) on the growth of hormone-dependent endometrial cancer cells (ISHIKAWA cell) in vitro. ISHIKAWA cells were plated into 96-well micoplates, treated with Dr. AglyMaxTM, and incubated for 24h. Cell proliferation was analyzed by ELISA using specific antibodies. We compared cell proliferation between Dr. AglyMax®at a concentration of 100 μM and a control without Dr. AglyMax®. Total RNA was isolated from cultured cells by the acid guanidine thiocyanatephenol/chloroform method. We also examined the changes in approximately 47, 000 gene expressions using a microarray method. Cell proliferation of the Dr. AglyMax®-treated group was lower than that of the control group (67%) (p<0.01) . A total of 1165 genes were down-regulated and 1114 genes were up-regurated following treatment with 100 iM Dr. AglyMax® . Our study suggests that daidzein-rich isoflavone aglycones inhibit endometrial cell growth and these genes, which are involved in steroid metabolism and cell cycles, are likely related to inhibition of cancer cell growth.
